Since the procurement of new and older antiepileptic drugs (AEDs) has become mostly centralized, insurance companies and pharmacy benefit management firms have been able to exert an increasing amount of influence on choice. This is causing challenges for neurologists who wish to prescribe specific AEDs or medications not included on their formularies. The situation can
Complete Reading